Send to

Choose Destination
Allergy Asthma Proc. 2001 Nov-Dec;22(6):359-66.

Safety of budesonide inhalation suspension (Pulmicort Respules) after up to 52 weeks of treatment in infants and young children with persistent asthma.

Author information

Allergy and Immunology Associates of Ann Arbor, P.C., Reichert Health Building, Suite R-1018, 5333 McAuley Drive, Ann Arbor, MI 48106, USA.


Three open-label extension trials evaluated the safety of budesonide inhalation suspension (BIS; Pulmicort Respules) in 670 children (8 months-9 years of age) with mild-to-severe persistent asthma. Patients were randomized to receive either BIS or conventional asthma therapy (CAT) for 52 weeks. The percentage of patients who discontinued because of clinical adverse events was low and similar among the CAT (0.4%) and BIS (0.7%) groups. After adjusting for length of time in the studies, there were no clinically relevant differences between the BIS and CAT groups in the type, incidence, or intensity of adverse events; vital signs or physical examination outcomes; or changes in clinical laboratory evaluations or oral fungal cultures.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center